SCHEMBL7052148

SCHEMBL7052148

CCCC(CP(=O)(CSc1ccccc1)OCC)C(=O)OCC

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.45
NPC1 O15118 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
KCNH2 Q12809 1/20 0.40
ALDH1A1 P00352 5/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 2/20 0.36
TSHR P16473 1/20 0.36
MAPT P10636 2/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MAPK1 P28482 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
EPHX2 P34913 2/20 0.35
PPARG P37231 2/20 0.35
PIN1 Q13526 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7049839 0.90 SMN1; SMN2 (0.40) POLBNPC1MEN1KMT2AKCNH2
SCHEMBL7050333 0.89 PPARG (0.39) POLBNPC1MEN1KMT2AALDH1A1
SCHEMBL7052860 0.88 EPHX2 (0.46) POLBNPC1MEN1KMT2AKCNH2
SCHEMBL7047032 0.88 HSD17B10 (0.38) POLBNPC1MEN1KMT2AKCNH2
SCHEMBL7049694 0.87 HSD17B10 (0.50) POLBNPC1MEN1KMT2AKCNH2
SCHEMBL7244415 0.82 POLB (0.38) POLBNPC1MEN1KMT2AALDH1A1
SCHEMBL7049610 0.82 ALDH1A1 (0.39) NPC1MEN1KMT2AALDH1A1HPGD
SCHEMBL7244226 0.82 PRNP (0.53) POLBNPC1MEN1KMT2AALDH1A1
SCHEMBL7049135 0.81 SMN1; SMN2 (0.37) POLBNPC1MEN1KMT2AALDH1A1
SCHEMBL7051089 0.79 SIRT5 (0.38) ALDH1A1HSD17B10MAPTSMN1; SMN2EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212067-A1 Matrix metalloprotease inhibitors CASTELHANO ARLINDO LUCAS (US) 2003-11-13 US disclosed
US-6579890-B1 Matrix metalloprotease inhibitors SYNTEX (U.S.A.) INC. 2003-06-17 US disclosed
US-6037472-A FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS SYNTEX (U.S.A.) INC. (US) 2000-03-14 US disclosed
EP-0793643-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1997-09-10 EP disclosed
EP-0726903-B1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX INC (US) 1997-07-16 EP disclosed
EP-0726903-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX INC (US) 1996-08-21 EP disclosed
WO-1996016027-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1996-05-30 WO disclosed
WO-1995012603-A1 MATRIX METALLOPROTEASE INHIBITORS________________________________ SYNTEX (U.S.A.) INC. (US) 1995-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212067-A1 Matrix metalloprotease inhibitors MMP7, MMP1, MMP3 POLB 1268/4885NPC1 927/4885MEN1 499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.